Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1299378 | 0.83 | USP2 (0.46) | USP2SMN1; SMN2USP30HRH3KDM4E | |
| SCHEMBL24089120 | 0.81 | USP2 (0.50) | USP2SMN1; SMN2USP30KDM4EMAPT | |
| SCHEMBL18192050 | 0.81 | POLB (0.34) | USP30DDB1CRBN | |
| SCHEMBL8018479 | 0.81 | USP30 (0.46) | USP2SMN1; SMN2USP30HRH3KDM4E | |
| SCHEMBL31170164 | 0.80 | USP30 (0.51) | USP2SMN1; SMN2USP30HRH3KDM4E | |
| SCHEMBL20475505 | 0.79 | HRH3 (0.50) | USP2SMN1; SMN2USP30HRH3KDM4E | |
| SCHEMBL20569460 | 0.79 | HRH3 (0.46) | USP2SMN1; SMN2USP30HRH3KDM4E | |
| SCHEMBL31008097 | 0.79 | USP30 (0.43) | USP2SMN1; SMN2USP30HRH3KDM4E | |
| SCHEMBL7309370 | 0.79 | USP2 (0.53) | USP2SMN1; SMN2USP30KDM4EMAPT | |
| SCHEMBL5895323 | 0.78 | USP2 (0.47) | USP2SMN1; SMN2USP30KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114369095-B | Aminopyrimidine compounds useful as SSAO inhibitors and methods for preparing the same | 伊莱利利公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-114369095-A | Aminopyrimidine compounds useful as SSAO inhibitors and methods of making the same | 伊莱利利公司 | 2022-04-19 | — | — | CN | disclosed |
| EP-3582780-B1 | AMINO PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS | LILLY CO ELI (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3582780-B1 | AMINO PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS | LILLY CO ELI (US) | 2021-10-13 | — | — | EP | disclosed |
| US-10471060-B2 | Amino pyrimidine compounds useful as SSAO inhibitors | ELI LILLY AND COMPANY (US) | 2019-11-12 | — | — | US | disclosed |
| US-10471060-B2 | Amino pyrimidine compounds useful as SSAO inhibitors | ELI LILLY AND COMPANY (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190275041-A1 | AMINO PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS | ELI LILLY AND COMPANY (US) | 2019-09-12 | — | — | US | disclosed |
| US-20190275041-A1 | AMINO PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS | ELI LILLY AND COMPANY (US) | 2019-09-12 | — | — | US | disclosed |
| US-10278970-B2 | Amino pyrimidine compounds useful as SSAO inhibitors | ELI LILLY AND COMPANY (US) | 2019-05-07 | — | — | US | disclosed |
| US-10278970-B2 | Amino pyrimidine compounds useful as SSAO inhibitors | ELI LILLY AND COMPANY (US) | 2019-05-07 | — | — | US | disclosed |
| US-20180296560-A1 | AMINO PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS | ELI LILLY AND COMPANY | 2018-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10278970-B2 | Amino pyrimidine compounds useful as SSAO inhibitors | DPYD, TYMP, NUDT1 | USP2 4800/4885SMN1; SMN2 1089/4885USP30 4334/4885 |
| US-20180296560-A1 | AMINO PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS | DPYD, TYMP, NUDT1 | USP2 4800/4885SMN1; SMN2 1089/4885USP30 4334/4885 |
| US-10471060-B2 | Amino pyrimidine compounds useful as SSAO inhibitors | DPYD, TYMP, NUDT1 | USP2 4800/4885SMN1; SMN2 1089/4885USP30 4334/4885 |
| US-20190275041-A1 | AMINO PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS | DPYD, TYMP, NUDT1 | USP2 4800/4885SMN1; SMN2 1089/4885USP30 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.